The Cost Of Coronavirus: Medtech Market Wins And Losses
Executive Summary
With the rapid global spread of the coronavirus, Medtech Insight looks at the predicted economic impact of the outbreak on the industry’s biggest businesses.
You may also be interested in...
Medtronic Sales Slump In Q4 2020 But CEO Reveals Appetite For Tuck-In Acquisitions
Medtronic's revenue for the fourth quarter of fiscal 2020 was down 25% year-year-over due to the COVID-19 pandemic. The hardest-hit segment was restorative therapies, which reported a 33% year-over-year decline in the quarter due to the drop off in deferrable procedures and capital purchases. For the full fiscal year, Medtronic's revenue was down 4.2% to $28.9bn.
Wall Street Tries To Guess The Impact Of Pandemic On Medtech Revenues
As the pandemic unfolds with an uncertain outcome, US securities analysts that cover publicly traded medtech companies are developing mathematical models to estimate the impact of the COVID-19 pandemic on medtech companies.
US Hospitals Cancel Elective Surgeries, Team Up With Medtechs To Find Remote-Monitoring Solutions
US health systems are canceling elective surgeries in response to COVID-19 to preserve critical resources. Massachusetts General Hospital works with medtechs to find technological solutions to keep patients and caregivers safe.